Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1

Conditions

Hemophilia A 2Lymphoma, Follicular 1

Interventions

Rituximab 91Cyclophosphamide 31Lenalidomide 28Bendamustine Hydrochloride 25Prednisone 21Vincristine 20obinutuzumab 17Doxorubicin 17fludarabine 14ibrutinib 13tazemetostat 9idelalisib 9Prednisolone 9Deoxycholic Acid 9parsaclisib 8zanubrutinib 7venetoclax 7tofacitinib 7tisagenlecleucel 5pembrolizumab 5ofatumumab 5ibritumomab tiuxetan 5duvelisib 5Gemcitabine 5Bortezomib 5durvalumab 4aflibercept 4R-CHOP protocol 4Methylprednisolone 4Methotrexate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Follicular × Factor VIII × Clear all
NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡